FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron’s says

Now that the FDA is resuming drug lab inspections in China three years after the pandemic started, biotech stocks such as Amicus (FOLD), BeiGene (BGNE), Novartis (NVS), and Coherus BioSciences (CHRS) could benefit, writes Josh Nathan-Kazis in Barron’s. Amicus’ Pompe drug was set to be manufactured by Chinese company WuXi Biologics before the FDA delayed its review of the drug because the agency’s inspectors could not visit the WuXi facility in China, while a new cancer treatment from BeiGene and Novartis was also delayed, the author says, noting that another cancer drug from Coherus was also in limbo. Reference Link